Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good to see Ifenprodil enrollment status is going strong. Some others are having a harder time with enrollments and continue to fluff. Maybe the cost or administration of their drug is an issue?
Saw this post and it's prediction but wont tell where...GLTA...
"From 8/12 to 9/30 is 49 days. ****** said they were at 86-87 patients on 8/12 and today at 102. That's 16 patients in 49 days, roughly 1 every 3 days.
If they need 42 more patients you're looking at 126 days."
Yes and some might be the flippers, even lie about buy / sell on this MB for some reason.
Too many attempts at the pump from JJ and too many OSs. Little meat on this call. Little meat on the PR really, just in planning stuff again, IMO. Of course GEM is taking profits, IMO. By the time I hung up the damage was already started...GLTA...
We were ahead of the pack back in May. That Data could have made this but Novotec/SK 1/2 stepped/failed us. We are in a pack now and Data is even more important as some have a 20% benefit. We now need 40%+ to separate us back to the top and be included in a cocktail. Still have confidence in the science, just need some early Data and management to give us some more meat. Fantastic news about accelerated enrollments...GLTA...
BTW
FU Dr Sik ,SK.
https://www.biospectrumasia.com/news/91/15885/algernon-re-purposes-ifenprodil-drug-against-covid-19.html
Please read the Flow chart that nelskof posted. When the word "Cure" is seen in a FDA response most will be happy. "Only" is your opinion too. Most here post their opinions with Links to support them...thank you Sir for the continuous repetitions ...
Our Killer dilution and offerings were done at that first fire sale. If strong positive Data is seem I would hope they strike while that Iron is HOT. Always been the plan to sell the Rights to their repurposed Drugs when they become a proven treatment and not engage in production, right.
Couple $B and I'm happy. With the comparatively low OS count it will be much easier than some companies with 10-20 times that.JMHO...GLTA...
A little disappointed by the current volume with the Harris pump today. Flippers are in charge or GEM is taking profits. Possible big event Wednesday. Some questions may be answered...
Good Flow chart on Emergency Use thru FDA, thanks to Nelskof.
All phase 2b/3 Trials need to complete Phase 2b and be approved to move to Phase 3.
The expanded access is for IV too and titled 'protocol'. My bad if I said Emergency use protocol. Not really my point with the name. Just that all Trials and Uses are for IV.
I believe and was asking if all agreed that the Emergency use was IV too.
Inhaler is a different set of Trials. right? and are not yet recruiting.
I post links to ClinicalTrials.Gov and quotes. Happy to have another opinion.
The company PR does not state exact method for Emergency use 'application', whether IV or Inhaler.?. I Assumed IV.
The current 2b Trial which is probably progressing to Phase 3 trial after reviewed data, the Expanded use authorization the IV version of RLF100. 3 doses of 12 hr Infusions. Some logistic issues and a called for price of 3X Remdesivir.$10K?.
We expect the new Emergency use protocol to be the IV version too, right?
The Inhaler trials are still planned and now could be paid for after last GEM financing. Inhaler may be the Golden ticket due to much easier logistics which could have easier worldwide distributions and pricing. Both Inhaler Trials are awaiting Recruitment status.
https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
I dont think so. The current IV Trials and Use and the start of an Inhaler Trial are funded, right. Possibly to include initial logistics and resulting income.
The 200m shares for $24M was the last kick start. GEM wants a return. Buyout for a few $B, OK by me too...
Are you pulling my leg? I suggested that before the 'in-house' partnership. I think that road is still wide open though, especially with strong results. Ask GEM.
I do think that it is important to differ between the current 'IV Trial/ Expanded use/Emergency use protocol application' and the 'Inhaler Trials'...GLTA...
My point was to have someone in management talk about their efforts through the rest of the planned distribution, not just the USA, not just how the pie is sliced as we wait for the hopeful EUA News and formal IV Trial Data. Logistics for the IV are different than the inhaler. My first post includes the quote from the IV trials and current IV Expanded Use Protocal...samicare...
The Inhaler is really the Golden Ticket, IMO. Distribution to worldwide markets and logistics are needed if an Emergency Use Authorization is granted.
Right now it looks like sell some after the news instead of waiting for in-house logistics/manufacturing/Inhaler. I hope for large volume to >$2...GLTA...
https://clinicaltrials.gov/ct2/show/NCT04453839?term=aviptadil&draw=2&rank=4
Most of the rest of the World is "minorities', non white. In the USA 35%+ suffering from effects of Covid are non/white. A large majority everywhere may not be able to purchase any Covid drug because of price and don't have healthcare and especially "Cadillac" policies.
In the USA we have some plans to distribute and pay for COVID medications and care. Other governments are doing their best, most better than here, I guess.
Aviptadil prices discussed here and from JJ will/May be 3X what a Remdesivir course costs and is probably/possibly worth much more, as Rem has a <20% benefit and early results for Aviptadil seem to indicate much better benefits, both as a Treatment and as a prophylactic.
BUT......
There IS a need to treat as many as possible both in the USA throughout it's whole populations and considerations for the rest of the world. I saw the 50-50% and 85-15% splits for IV(?**) which is about profits, but maybe I missed plans for distribution partners.
I saw/heard about work toward these goals but think announcing actual progress of plans or even Discussions with other Govs/Countries/Groups(!!) could support the pps for a better base, while we wait for the bigger news.
Inhaler products are the Golden ticket. That's why there are TWO trials planned for them, IMO. But...
I (We?) haven't seen the EUA and I Ass-ume it is for the IV.?**. Recruiting Trial in progress is IV.
Expanded access...
**Patients will be treated with 12 hour infusions of RLF-100 at ascending doses of 50/100/150 pmol/kg/hr on 3 successive days
News Rule with these guys and all stocks.IMO.
Drugs with significant positive Data will be in demand. Period.
Biggies must still be looking to find even a partial solution or treatments as part of a more successful short and long term answer to issues caused by COVID.
World wide cases still grow, even before the 'winter' flu season and expected 2nd waves.
Brazil, India, US etc
News Rules, Good or Bad, IMO...
Not good news for Roche.
"Meanwhile, the difference in time to hospital discharge or difference in time to improvement in ordinal clinical status to day 28 was not significant between the study drug and placebo groups.
Roche added that time to clinical failure to day 28 was longer in the Actemra arm compared with the placebo group, but was not statistically significant.
Furthermore, no statistical difference was observed in mortality between the study drug and placebo arms by day 28."
Worse news for Kodak.
NEW YORK, NY / ACCESSWIRE / September 25, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Eastman Kodak Company (NYSE:KODK)
CONTACT JAKUBOWITZ ABOUT KODK:
https://claimyourloss.com/securities/eastman-kodak-company-loss-submission-form/?id=9617&from=1
Class Period : July 27, 2020 - August 11, 2020
Lead Plaintiff Deadline : October 13, 2020
According to a filed complaint, defendants failed to disclose that the Company had granted its Executive Chairman, James Continenza, and several other Company insiders millions of dollars' worth of stock options immediately prior to the Company publicly disclosing that it had received the $765 million loan, which Defendants knew would cause Kodak's stock to immediately increase in value once the deal was announced. In addition, while in possession of this material non-public information, Continenza and other Company insiders purchased tens of thousands of the Company's shares immediately prior to the announcement, again at prices that they knew would increase exponentially once news of the loan became public.
I guess that is bad news for them? Maybe when our Trials have possible better results they may be among some Biggies interested to talk with Mr Monroe.?. Just a couple $B for the Rights to Ifenprodil.?...GLTA...
"Meanwhile, the difference in time to hospital discharge or difference in time to improvement in ordinal clinical status to day 28 was not significant between the study drug and placebo groups.
Roche added that time to clinical failure to day 28 was longer in the Actemra arm compared with the placebo group, but was not statistically significant.
Furthermore, no statistical difference was observed in mortality between the study drug and placebo arms by day 28."
It's 2b progressing to a 3.?. 144 patients for the initial 2b Trials part and enough to show significant signals.?. If significant data, then moving to a much larger Phase 3. (4X+ larger?). Maybe I'm wrong, happens often...GLTUA...
Thanks for the conversations, nicer forum recently.
OT; Raining, early Coho and Chinook are running and going to the NF N* . I'll plug in sometime, hope we're right about fishing this weekend, at least...GLTA...
Those #'s were already posted and in report. I think they MAY just be selling enough to cover the past investment and some profit, the rest is Gold (possibly) but the big sellers are covering all bids IMO. 45% held by Gem and insiders.
If I'm wrong (often happens) it is also the folks that got in @ the >$.4's blast off and some traders with the smaller / lower bids. Big chunks are the same suspects over weeks, right? JMHFO...
The reason that the share information doesn’t matter to me, is that it will get bought by one of the big 10 pharma companies."
Maybe there will be another chance After Data and movement to Phase 3 of IV or the start of enrollment or success of Inhaler Trials. 2 Inhaler Trials now so this must be their main focus and target for distribution. IV has logistic issues, IMVHO.
They partnered In-House and are seeking Subs/contract work for distribution and inhaler production. Right?
Yes, possible that the Phase 2, 144 patients, part of the Phase 2/3 Clinical Trial is full. We can hope. Movement to Phase 3 will be a significant Milestone and thoroughly Publicized...IMO...
Same sellers probably meaning GEM is still the one. I would hope they would let this raise to the $.70's before more PRs , DATA or other news. The raise will bring in higher VOLUME, DUH, which we / THEY NEED, Duh...GLTA...
If the IV recruitment was Full wouldn't it be Pr'ed? I think this just refers to the sites where patients are recruited...JMO...
2nd Inhaler Trial is New...
Aren't the partnerships done, Nrx/Rlf?.
No buyout as I hoped to pass the ball and cash out. Doing things in house and with contract subs? Do some expect GSK to get involved Now?
Hope you DHs are happy with those couple hundred bucks. Could have left the pps or supported it.
https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2
IV = recruiting updated 8-31
New Inhaler Trial not yet recruiting 9-7
Hmmmm, waiting for a MC of $12B to $50B, I also hear 50-85% of 150K patients a month @ $7K+, could be. We need alot of holders to feel that way ...GLTA...
Gee, we all sure wish GEM and insiders would have some of that confidence in the company. A $.7's+ base would be nice before Data. At a few M shares a day they'll never sell them all, so are they less confident than you/us?...GLTA...
Who's gona buy their 23M+ shares. They killed the stock with the 14M self gifts thefts from 12 /18 instead of running the company First. I dont think they are allowed to sell anyway under BK. Hope they all end up in JAIL.
It amazes me that they were a leading CBD company with Prana and had an early entrant but fkt up one deal after another...Hail damage? Presenting deals as Done. Fire at customer. Jamaica. SC. Tennessee. Proprietary extraction method. 10k lbs a day processor, other lies, as bad as KSHB with an even lower sewage management. Should have followed Tony Veruza out the door. Vent over along with YEARS of investment.
KARMA they are homeless/companyless/friendless/
They SURE *ucked Friends, Family, Employees and Investors by total lies and siphoning their Absurd salaries. I HOPE they GO TO JAIL and have a Clawback of past Stolen Income/Properties.IE JAMAICA, etc ...GLTA...Somewhere else...
Tony was right to sell, I should have too...
Good news, but it will be slow movement up it seems, IMO. My (relatively small) $.65 bid was filled @$.61. Saw it last night and slept in with hope of much more interest after setting the buy last night. I wanted to help push and not be one of those 4 digit lowballers/charters/penny flippers, but GEM flooding, IMHFO...
Catalysts like Approvals for Emergency use, start of Inhaler recruitment and top line data Data will make the volume we apparently need. Gonna need much more volume to overcome GEM's influence, IMHFO.
Unfortunately there are 200k new cases, 33M confirmed world wide, with 1m deaths. Plenty of NEEDS for Something that works statistically significantly and will be available. Success of other drugs and treatment combinations now being used range between 10% and 30% at best, so far...GLTA...
Best Wishes to Penguin and all those suffering from COVID and it;s after affects and to all their Families and Friends. God Bless those accepting the Risks of Clinical Trials along with their Nurses and Doctors as they have EARNED Veteran Status...IMO...
GLTA on this MB too...Adios...
Astrocytes express a wide range of G-protein coupled receptors that trigger release of intracellular Ca2+, including P2Y, bradykinin and protease activated receptors (PARs). By using the highly sensitive sniffer-patch technique, we demonstrate that the activation of P2Y receptors, bradykinin receptors and protease activated receptors all stimulate glutamate release from cultured or acutely dissociated astrocytes. Of these receptors, we have utilized PAR1 as a model system because of favourable pharmacological and molecular tools, its prominent expression in astrocytes and its high relevance to neuropathological processes. Astrocytic PAR1-mediated glutamate release in vitro is Ca2+ dependent and activates NMDA receptors on adjacent neurones in culture. Activation of astrocytic PAR1 in hippocampal slices induces an APV-sensitive inward current in CA1 neurones and causes APV-sensitive neuronal depolarization in CA1 neurones, consistent with release of glutamate from astrocytes. PAR1 activation enhances the NMDA receptor-mediated component of synaptic miniature EPSCs, evoked EPSCs and evoked EPSPs in a Mg2+-dependent manner, which may reflect spine head depolarization and consequent reduction of NMDA receptor Mg2+ block during subsequent synaptic currents. The release of glutamate from astrocytes following PAR1 activation may also lead to glutamate occupancy of some perisynaptic NMDA receptors, which pass current following relief of tonic Mg2+ block during synaptic depolarization. These results suggest that astrocytic G-protein coupled receptors that increase intracellular Ca2+ can tune synaptic NMDA receptor responses.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2170820/
Might want to look up NMDA receptor agonist/glutamate, Drugs in Trials
Astrocytes express a wide range of G-protein coupled receptors that trigger release of intracellular Ca2+, including P2Y, bradykinin and protease activated receptors (PARs). By using the highly sensitive sniffer-patch technique, we demonstrate that the activation of P2Y receptors, bradykinin receptors and protease activated receptors all stimulate glutamate release from cultured or acutely dissociated astrocytes. Of these receptors, we have utilized PAR1 as a model system because of favourable pharmacological and molecular tools, its prominent expression in astrocytes and its high relevance to neuropathological processes. Astrocytic PAR1-mediated glutamate release in vitro is Ca2+ dependent and activates NMDA receptors on adjacent neurones in culture. Activation of astrocytic PAR1 in hippocampal slices induces an APV-sensitive inward current in CA1 neurones and causes APV-sensitive neuronal depolarization in CA1 neurones, consistent with release of glutamate from astrocytes. PAR1 activation enhances the NMDA receptor-mediated component of synaptic miniature EPSCs, evoked EPSCs and evoked EPSPs in a Mg2+-dependent manner, which may reflect spine head depolarization and consequent reduction of NMDA receptor Mg2+ block during subsequent synaptic currents. The release of glutamate from astrocytes following PAR1 activation may also lead to glutamate occupancy of some perisynaptic NMDA receptors, which pass current following relief of tonic Mg2+ block during synaptic depolarization. These results suggest that astrocytic G-protein coupled receptors that increase intracellular Ca2+ can tune synaptic NMDA receptor responses.
Thesis in Trial application. By blocking Cy storm may...
The study is posted at https://clinicaltrials.gov/ct2/show/NCT04360096 . The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure. If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.
Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx said, “Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro).[1] We are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19. By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung’s ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection.”
Your post is unclear. Aviptadil is just another method of attacking the Cy storm being PROVEN in Clinical Trials. WE are all awaiting DATA from Trials here. Thesis are NOT FDA accepted DATA>>> Yes I own shares, plenty.
No, Aviptadil is NOT tho only Drug IN TRIALS (2b/3) that is effective against the Cytokine storm. Do your DD, Post links. I would but Ihub MBs do not allow it, except for some where open discussions are held along with posts with DD, not DBS...
How about throwing in Storage, Logistics and administration. Getting Cancer infusions costs about $3k out of 10k per dose and that is for a 1 hour IV infusion in a chair, not in a bed with apparatuses.
I would change the calcs some to account for these as the $5k - $10k is certainly not all profit.
It was posted that there are 300k new cases, you say 500k +/month, and RLF will make 150k doses. This certainly leaves a huge untreated patient group. Plenty of room for other solutions or combinations. Certainly some will be less expensive. Some will be much more effective than Rem or Coquin. There are other drugs in Trials with a Much lower cost and possibly as effective. IMO...GLTUA...
Links please, TIA... Maybe an "IMO", if there are no links you will post. Maybe ask GEM/Insiders?
It seems some poster doesn't get "it" and especially the OTC. I am posting comparative info and am attacked for the messenger's opinions,
I THINK THIS DRUG/STOCK IS BETTER for the reasons posted. I THINK racing to in-house production WITHOUT a Biggie is not smart and I HOPE OUR management will SELL the Rights to Ifenprodil, when/IF proven sufficiently, to have a better result than another Drug with issues I dont see here or actions I dont like.
How about taking recent profits and being happy/happier. It Works... How about some Positive INPUT HERE?... Complaining or disparaging others is NOT a significant investment strategy, IMHFO...
I have NOT said "Ifenprodil" there. Just implied that there are other Drugs to consider as that wild pumpfest succumbs to fast/BAD decisions, IMHFO...
"Let's just keep our story our story." please explain this comment????????????????????????????????????????????????????????????????
JB, PM / LOL... I had hope we would at least test past highs... Long term play now or for flipper pennies so far. Another on the waiting shelf?..JMO...
Ifenprodil is listed in table 1 but they didnt include Trial numbers... The biggies are taking up most of the air but Results will matter and I dont see anything but theories and Rem/CoQuin and mubs (immunos) mainly pumped with limited results so far. JMO...
https://www.sciencedirect.com/science/article/pii/S0014299920306609
NO, I posted here about excessive pumping there, comparing the OS counts and the decision to in house partner prematurely as compared to getting a Biggie involved, IMO. Ridiculous projections. No tickers posted, just assuming youall(?) understood.
The issue of Them NOT selling their product as a business model and the delay caused by the attempt of going it alone/in house. The small amount of doses to be produced and logistics issues. I even quoted your new virus patient count compared to available supplies / future supplies for that.
A much higher production volume can be achieved for Ifenprodil and at a much lower Price to patients without logistic issues, IMO. They both attack the Cy storm but in different ways. I ASSUME our drug may attract stronger interest from a Biggie.
I did not see your post, bring it here for a relevant discussion? This board has been slack lately. Everything there gets buried by tripe. Sure doesn't look like your pps or my hopes will appear soon there. That's the difference between 2.4B OS and 200M OS, etc, etc...
I should have commented to Shell not myself about this, yes.